Aim immunotech announces first subject dosed in the netherlands for phase 1b/2 study evaluating ampligen® (rintatolimod) in combination with astrazeneca's imfinzi (durvalumab) for the treatment of pancreatic cancer

Phase 1b portion of the study expected to be completed within six months phase 1b portion of the study expected to be completed within six months

AIM Ratings Summary

AIM Quant Ranking